Silver Book

Silver Book Fact

Effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset

A study of the effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset found an estimated impact on long-term health outcomes of 564 quality-adjusted life-years saved per 1,000 patients over 30 years.

Fagan, SC, LB Morgenstern, A Petitta, RE Ward, BC Tilley, JR Marler, SR Levine, JP Broderick, TG Kwiatkowski, M Frankel, TG Brott, and MD Walker; for the NINDS rt-PA Stroke Study Group. Cost- Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke. Neurology. 1998; 50(4): 883-890. http://www.neurology.org/content/50/4/883.abstract

Reference

Title
Cost- Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Publication
Neurology
Publication Date
1998
Authors
Fagan, SC, LB Morgenstern, A Petitta, RE Ward, BC Tilley, JR Marler, SR Levine, JP Broderick, TG Kwiatkowski, M Frankel, TG Brott, and MD Walker; for the NINDS rt-PA Stroke Study Group
Volume & Issue
Volume 50, Issue 4
Pages
883-890
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Per-patient annual cost of treating stroke in atrial fibrillation patients
    The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
  • The projected economic value of eliminating deaths from stroke is $7.6 trillion.  
  • If antihypertensive medication were widely used, it would result in an estimated increase in life expectancy (averaged over the entire population) of 0.5 years in men and 0.4 years in…  
  • According to the National Institutes of Health, use of the clot-busting drug t-PA saves $4,400 per patient in hospitalization and nursing home costs.